Indeed, efficacy of EZH2 inhibitors in malignant rhabdoid tumours is dependent on the activity of NSD1, reinforcing the importance of this balance of Polycomb and H3K36me2 domains across different cancers (Drosos et al., 2022). The gene discussed is EZH2; the disease is cancer.